Trius Therapeutics Inc. (TSRX: Quote) announced the U.S. FDA has designated its Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product (QIDP). Trius received the designation for its current Phase 3 program of tedizolid for acute bacterial skin and skin structure infections as well as the planned Phase 3 program for hospital-acquired/ventilator-associated bacterial pneumonia. The designations were granted for both the intravenous and oral dosage forms of tedizolid.
The QIDP designation will enable Trius to benefit from certain incentives for the development of new antibiotics, including priority review and eligibility for fast-track status.
Click here to receive FREE breaking news email alerts for Trius Therapeutics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News